5,000 Alzheimer's patients monitored for brain side effects of new drug
NCT ID NCT06322667
First seen Feb 01, 2026 · Last updated May 23, 2026 · Updated 11 times
Summary
This study watches 5,000 people with early Alzheimer's who are taking lecanemab in regular medical care. The goal is to learn about brain changes called ARIA that can happen with this drug, and how doctors manage treatment when these changes occur. No new treatments are being tested; instead, researchers are collecting safety information from real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Eisai trial site 1
RECRUITINGTokyo, Japan
-
Eisai trial site 2
RECRUITINGHiroshima, Japan
-
Eisai trial site 3
RECRUITINGKyoto, Japan
Conditions
Explore the condition pages connected to this study.